Announcements

April 26, 2018

Genetic Signatures ASX: GSS Positive Trial Results Presented at ECCMID Madrid, Spain 2018

Genetics Signatures GSS – Appendix 4C Quarterly Report March 2018

April 20, 2018

Genetics Signatures GSS – European approval expands product suite

February 28, 2018

Genetics Signatures GSS – Appendix 4D and Half Year Financial Statements February 2018

January 25, 2018

Quarterly Activities Report – GSS Appendix 4C 31 December 2017

May 23, 2018

Genetic Signatures (ASX: GSS) Investor Presentation, May 2018

Genetic Signatures Limited (ASX: GSS) Investor Presentation, May 2018

Click here to read more

 

October 22, 2018

Genetic Signatures (ASX:GSS) – Appointment of CFO

September 17, 2018

Date of 2018 Annual General Meeting of Shareholders (GSS: ASX)

Genetic Signatures Limited (ASX: GSS) has announced its date of 2018 Annual General Meeting. For more information click the link

Date of Annual General Meeting 2018

 

September 10, 2018

Genetic Signatures’ CEO Dr. John Melki interview by Proactive Investors

Genetic Signatures’ CEO Dr. John Melki was recently interviewed by Proactive investors at the ASX Small and Mid-Cap Conference.

See the link below to learn more about our 3baseTM technology and EasyScreenTM assays, and how we’re improving patient outcomes.

For more information click the link:  Genetic Signatures’ clinical trials demonstrate product efficacy.

September 7, 2018

Genetic Signatures article from The Australian Financial Review.

Genetic Signatures featured in The Australian Financial Review.

For more information click the link:  Winning the war on superbugs

September 5, 2018

Genetic Signatures’ CEO Dr. John Melki presenting at the inaugural ASX Small and Mid-Cap Conference 6th September, Sydney, Australia.  

Join ASX for the inaugural ASX Small and Mid-Cap Conference, showcasing emerging leaders in the small and mid-cap category. This is a unique opportunity to hear from a broad range of ASX-listed companies and their CEOs in the comfortable surrounds of the International Convention Centre at Darling Harbour.

This conference aims to welcome over 400 attendees from the finance industry, with an emphasis on SMSF / sophisticated investors.

Visit John and the team to learn more about the directions of Genetic Signatures.

For more information regarding the conference click here, and the presentation may be viewed here

August 28, 2018

Genetic Signatures (ASX:GSS) – Appendix 4E and 2018 Financial Report